Plain-English translation of NCT05618925 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new therapy called CD19 t-haNK, which uses specially engineered immune cells to fight lymphoma. The study will test this medication alone first, then combined with one or two additional cancer drugs, to see if it is safe and whether it helps people whose lymphoma has returned or stopped responding to standard treatments.
People with aggressive lymphoma that has come back after chemotherapy or no longer responds to treatment often have very few options left. This medication is designed to harness the body's own immune system to attack cancer cells in a new way, offering hope for patients who have exhausted other therapies.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy to prepare your body, followed by infusions of the new immune cell therapy through a central line (a special tube placed in a large vein). The study involves cycles of treatment separated by rest periods, with the medication given alone initially, then combined with one or two other drugs. You would need regular hospital or clinic visits for infusions, blood work, and scans over several months to monitor how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States